Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Hemmingsen, Bianca ^a   Sonne, David Peick ^a   Metzendorf, Maria Inti ^b   Richter, Bernd ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; SULFONYLUREA; ANTIDIABETIC AGENT; BENZAMIDE DERIVATIVE; CYCLOHEXANE DERIVATIVE; GLIMEPIRIDE; GLUCOSE BLOOD LEVEL; METFORMIN; NATEGLINIDE; PHENYLALANINE; SULFONYLUREA DERIVATIVE;

ARTICLE; COCHRANE LIBRARY; DISEASE COURSE; EMBASE; IMPAIRED GLUCOSE TOLERANCE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ADULT; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASE; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECRETION (PROCESS);

ADULT; BENZAMIDES; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MIDDLE AGED; PHENYLALANINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84991383865     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.cd012151.pub2     Document Type: Article

References (75)

1. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55(5):1430-5. [PUBMED: 16644701]
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20(7):1183-97.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-20.
4. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl 1):S12-54. [PUBMED: 18165335]
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9. [PUBMED: 20042775]
6. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 2015;38(Suppl 1):S1-93. [PUBMED: 24357209]
7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 2006;355(23):2427-43.
8. Bell ML, McKenzie JE. Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures. Psycho-oncology 2013;22:1738-47.
9. Beller EM, Chen JK, Wang UL, Glasziou PP. Are systematic reviews up-to-date at the time of publication?. Systematic Reviews 2013;2:36. [2046-4053: (Electronic)]
10. Black C, Donnelly P, McIntyre L, Royle P, Shepherd JJ, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004654.pub2]
11. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes & Metabolism 2006;32(2):113-20. [PUBMED: 16735959]
12. Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P. Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. Journal of Clinical Oncology 2014;32:4120-6.
13. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
14. Centers for Disease Control and Prevention. 2014 National Diabetes Statistics Report. http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html (accessed 15 October 2015).
15. Cheng C, Kushner H, Falkner BE. The utility of fasting glucose for detection of prediabetes. Metabolism: Clinical and Experimental 2006;55(4):434-8. [PUBMED: 16546472]
16. https://clinicaltrials.gov/ct2/results?term=prediabetes+drugs&Search=Search. Accessed 12 February 2016.
17. Corbett MS, Higgins JP, Woolacott NF. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods 2014;5:79-85.
18. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technology Assessment (Winchester, England) 2003;7(27):iii-x, 1-173. [PUBMED: 14499048]
19. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism: Clinical and Experimental 1989;38(4):387-95. [PUBMED: 2657323]
20. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 2002;346(6):393-403. [PUBMED: 11832527]
21. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009 Nov 14;374(9702):1677-86. [DOI: 10.1016/S0140-6736(09)61457-4; PUBMED: 19878986]
22. Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care 2014;37(4):922-33. [PUBMED: 24652723]
23. Egbewale BE, Lewis M, Sim J. Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study. BMC Medical Research Methodology 2014;14:49. [DOI: 10.1186/1471-2288-14-49]
24. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine 2001;344(18):1343-50. [PUBMED: 11333990]
25. http://www.drugs.com/uk/gliclazide-80-mg-tablets-leaflet.html. Assessed December 2015.
26. http://www.drugs.com/pro/glimepiride.html. Assessed December 2015.
27. Gosmanov AR, Wan J. Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. The American Journal of the Medical Sciences 2014;348(3):191-4. [PUBMED: 24556928]
28. McMaster University (developed by Evidence Prime, Inc.). GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015.
29. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety 2000;22(4):313-20. [PUBMED: 10789825]
30. Hemmingsen B, Krogh J, Metzendorf MI, Bernd R. Dipeptidyl peptidase 4 inhibitors and glucagon like peptide 1 analogues for prevention or delay of type 2 diabetes and its associated complications. Cochrane Database of Systematic Reviews (Submitted), Issue -.
31. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
32. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60.
33. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2009;172(1):137-59.
34. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Statistics in Medicine 2011;30(9):903-21. [PUBMED: 21190240]
35. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
36. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
37. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 2013;185(4):E201-11.
38. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR & ICH Guidelines. PA 19063-2043. USA: Barnett International/PAREXEL, 1997.
39. International Diabetes Federation. IDF Diabetes Atlas. 6th Edition. Brussels: International Diabetes Federation, 2013.
40. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32(7):1327-34. [PUBMED: 19502545]
41. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96. [PUBMED: 22526604]
42. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002;51(7):2170-8. [PUBMED: 12086947]
43. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365]
44. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
45. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
46. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
47. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009;302:977-84.
48. McCall AL. Clinical review of glimepiride. Expert Opinion on Pharmacotherapy 2001;2(4):699-713. [PUBMED: 11336617]
49. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
50. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25(10):1845-50. [PUBMED: 12351489]
51. Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 2013;56(7):1489-93. [PUBMED: 23584433]
52. The NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. The New England Journal of Medicine 2010;362:1463-76. [PUBMED: 20228402 ]
53. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28(12):1039-57. [PUBMED: 510803]
54. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes, Obesity & Metabolism 2012;14(9):803-9. [PUBMED: 22486923]
55. Phillippe HM, Wargo KA. Mitiglinide for type 2 diabetes treatment. Expert Opinion on Pharmacotherapy 2013;14(15):2133-44. [PUBMED: 23992284]
56. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93; discussion 661-6. [PUBMED: 9408720]
57. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
58. Riley RD, Kauser I, Bland M, Thijs L, Staessen JA, Wang J, et al. Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. Statistics in Medicine 2013;32(16):2747-66.
59. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Annals of Internal Medicine 2012;157(9):601-10. [PUBMED: 23128859]
60. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European Heart Journal 2011;32(15):1900-8. [PUBMED: 21471135]
61. Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 2012;72(2):249-72. [PUBMED: 22268393]
62. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Annals of Internal Medicine 2011;154(5):303-9. [PUBMED: 21357907]
63. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
64. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976;25:1129-53.
65. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65. [PUBMED: 9742977]
66. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53. [PUBMED: 9742976]
67. Viera AJ. Predisease: when does it make sense?. Epidemiologic Reviews 2011;33:122-34.
68. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
69. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15(7):539-53.
70. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. WHO, 1999.
71. World Health Organization/ International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. http://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf 2006; Vol. Assessed October 2015.
72. Wong SS, Wilczynski NL, Haynes RB. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc 2006;94(4):451-5.
73. Wong SSL, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. Journal of the Medical Library Association 2006;94(1):41-7.
74. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
75. Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. BMJ 2014;349:g4485.